Aker BioMarine ASA

As of June 30, 2025, Aker BioMarine ASA carries a market capitalization of 5.30B, placing it among publicly traded companies globally. Its enterprise value stands at 6.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aker BioMarine ASA's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2025, Aker BioMarine ASA has 87.69M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Aker BioMarine ASA maintains a current ratio of 2.63, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Aker BioMarine ASA recorded an income tax benefit of -3.02M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on September 25, 2026, Aker BioMarine ASA's stock has gained approximately 35.33% over the past 52 weeks.

As of June 30, 2025, Aker BioMarine ASA holds 196.38M in cash and equivalents against 1.84B in total debt, resulting in a net debt position of -196.38M. Total book value stands at 1.51B, with working capital of 1.21B providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Aker BioMarine ASA paid dividends of 45.15 per share.